arbaclofen (Pending FDA Approval)

Brand and Other Names:Ontinua ER

Dosing & Uses

Spasticity

Pending FDA approval for treatment of spasticity in patients with multiple sclerosis (MS)

Next:

Pharmacology

Mechanism of Action

Prodrug that is converted R-enantiomer of baclofen; allows for oral dosing with higher bioavailability

Inhibits synaptic transmission through spinal reflex arcs via hyperpolarization of primary afferent fiber terminals; this inhibition may decrease in muscle spasticity

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.